International Cooperation_China National Biotec Group Company Limited

Cooperation Partners

  • World Health Organization
  • BILL & MELINDA GATES foundation
  • PATH
  • dcvmn
  • World Health Organization

In terms of international cooperation, CNBG has built a communication network covering the World Health Organization, Gavi, UNICEF, and DCVMN among other major international organizations in the health sector, as well as partnerships with non-governmental organizations including the Bill & Melinda Gates Foundation and Seattle-based health organization PATH. The communication network and partnerships help expand its presence in the international market, acquire market information, make global strategies, and seek policy and resources support. A series of pragmatic cooperation in polio, JE, rotavirus and TB vaccines, quality evaluation and ETEC have been conducted, effectively improving Chinese biopharmaceutical industry’s participation in international public health affairs and expanding the industry’s global influence.


In June, 2011, CNBG and Bill & Melinda Gates Foundation (BMGF) signed the Memorandum of Understanding on Strategic Partnership for Global Health. Subsequently, Tiantan Bio and BMGF signed a financial support agreement for the bOPV project on November 15, 2011. The project received US$7.35 million in grants and US$16.38 million in low-interest loans from BMGF.

A new bivalent OPV production base with an annual capacity of 240 million doses has been put into operation, which has since provided a cumulative supply of 300 million doses of vaccine for China’s polio eradication program, ensuring the smooth conversion from trivalent to bivalent polio vaccine in China.

It passed the WHO prequalification in December 2017.

It 2017, it obtained a long-term UNICEF purchase order for the supply of a total of 70 million doses of bivalent polio vaccine products to the UNICEF over the next two years.

Production Expansion and WHO Prequalification of Inactivated Poliomyelitis Vaccine bOPV

The vaccine passed the WHO prequalification in 2013.

China’s first vaccine product prequalified by the WHO.  

The world’s first live attenuated ethyl vaccine prequalified by the WHO.

It has been registered in 11 countries and included in the immunization programs of Nepal, India, Sri Lanka, South Korea and Thailand. It has provided support to Laos, Myanmar, Indonesia, the Philippines and Cambodia through the GAVI/UNICEF program.

By the end of 2017, more than 400 million doses had been supplied to the international market.

WHO Prequalification of Live Attenuated Ethyl Vaccine

In 1989, under the support of the Ministry of Health, Beijing Institute of Biological Products and Shenzhen Kangtai Biological Products Co., Ltd. negotiated with Merck & Co Inc the introduction of the full set of production technology of recombinant hepatitis B vaccine.

Global Market

Acting upon the Belt and Road Initiative, CNBG has been expanding international exchanges and cooperation in infectious disease prevention and control. Faithfully discharging its duties as a member of the Developing Countries Vaccine Manufacturers Network (DCVMN), it has been working to increase the number of vaccine manufacturers in developing countries and enable them to go global.

In 2019, CNBG had 56 valid overseas registration certificates covering eight categories of pharmaceutical products in 34 countries. It also acquired two new certificates of producing JE vaccines in the Philippines and Indonesia. And its nine certificates for hepatitis B hyper-immune globulin and botulinum toxin-A in eight countries were renewed.

From January to November 2019, CNBG logged more than US$32.6 million in foreign trade. Exports of various vaccines, blood products, therapeutic bio-pharmaceutical products and medical cosmetics products approached 10.95 million doses in 2019.

To let more lives be cared for and cared for, China Bio is constantly working hard.

Home>International Cooperation